Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
O never mind I see they just did one. Lots of medical stocks do this I’ve noticed after any big news. Should be outlawed
Are people not holding tonight incase of an offering?
i had 2.26 bid premarket. got cheap and moved to 2.22. went 2.50 and based. and ran...damn
$ICCM has $667k DEBT
https://finviz.com/quote.ashx?t=ICCM&p=d
36m OS
10m float
100M VOLUME
the explanation is hidden secret
the reason why people arent honest with the government is because the government isnt honest with people
https://stockcharts.com/h-sc/ui?s=ICCM&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/ICCM/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100
https://www.barchart.com/stocks/quotes/ICCM/opinion
Huge open gap @ $1.00
I missed that one Watching EDSA low float ,so many so my scanner
yep 5m vol yest 70M today, the big money wants to push it, based off what they say happened yesterday
$ICCM: Churning over and over on lowfloat, VWAP bounce
YUppppppppppp........... this isn't done yet
69Milly vol, wow
Love that bounce.............. here comes $5 break and boost momentarily
GO $ICCM
here comes another bounce
don't remind me . I always go for 100% the Premarket resistance @3.21 Is why I left I was expecting a sell off at market open .
2.30 - 4.73 you could have doubed your $$
just sayin
ICCM: Well, CONGRATS to You, Capt. S-L! (LOVE-IT!!!)
$ICCM: Added 10k on that 3.35 dip
Couldn't help myself
Could retest that $10 it did AH yesterday.
GOt a $3 stop on it as well
It is great newssssssssssssssssssss
GO $ICCM
I totally Agree With you on the balance .It's something I need to work on. I'm just too in love with the market. Especially That I'm able to follow the Trends right now. Yesterday I was busy fighting with my broker over COSM gains.
Thanks, bro. That was the tip to buy and hold.
$ICCM: I'm not very active PostMarket
Im off living the rest of my life when the markets close.
Just a personal policy of mine, I leave it to others to stay and dilly dally after.
Trying to balance Time and MONEY as best as possible.
$MDGL yesterday with those $100 Jan2023 calls surge was Mindblowing
GO $ICCM
Your late run was yesterday post market I just exited @3.06, too much resistance above 3.20. Seem like you need to get a post market scanner.
$ICCM: This PR 1month ago was the key
No surprise this badboy is boosting now.
Nice find !
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170396435
GO $ICCM
I bought at $2.44, I will sell at $10. If it takes 1 year or 3, I don't mind.
break 3.21 and run again
maybe see 5+?
sometime today
algos are on it
I saw 11,84 and I was happy with 6,50 lmao. That HOD was freaking insane buddy!
2.30-$3 you trade the bounce?
If someone bought this when it was 1000% up and they didn't sell when it started to fall, then they don't decerve to be a baggie......
the mm's took control back
last night was crazy 11.84
aaaand everyones a bagholder
IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results
https://finance.yahoo.com/news/icecures-prosense-safe-effective-treating-210500592.html
ICESECRET study interim findings presented at the Urological Association Conference in Eilat, Israel
ProSense was found to be a safe and effective treatment method for renal lesions smaller than 5 cm in patients not suitable for kidney-preserving surgery
ProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries
CAESAREA, Israel, Dec. 19, 2022 /PRNewswire/ --- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced interim results from the ICESECRET study for the treatment of patients with small renal masses ("SRM") who cannot be offered kidney-preserving surgery. Data were presented on December 14, 2022 at the Urological Association Conference in Eilat, Israel. The presentation titled "Renal Mass Cryoablation - Interim Analysis ICESECRET Study" was delivered by Dr. Nasir Said of Bnai Zion Medical Center.
According to the presentation, out of the 115 patients enrolled, 107 patients (112 lesions) returned for follow-up with a mean duration of 22.8 months and a range 12-60 months.
In a subgroup of patients with no previous history of kidney cancer on the same kidney and a lesion ≤3 cm, an 89.5% recurrence-free rate was observed at a mean follow-up time of 22.2 months when the procedure protocol was followed.
The recurrence-free rate was 85.1% for the 107 patients (91 patients, including 13 patients who underwent a second cryoablation), at a mean follow-up period of 16.5 months.
5 serious adverse events were reported, 4 of which were of mild severity and were treated conservatively and resolved within 1-5 days, with one severe complication of a new onset of ipsilateral hydronephrosis 7 months after the cryoablation procedure that led to nephrectomy.
Cryoablation time and hospitalization time were relatively short, up to approximately 25 minutes and 2 days, respectively.
The presentation concluded that, based on these interim results, cryoablation is safe and effective for treating renal masses under 5 cm.
According to the American Journal of Roentgenology, small renal masses, which may be malignant or benign tumors in the kidney, have been rising in incidence over the past two decades. According to the American Cancer Society, in 2022, in the U.S., an estimated 79,000 new cases of kidney cancer will be diagnosed, with about 14,000 dying from the disease. Globally, there were more than 430,000 new cases of kidney cancer in 2020 and about 180,000 deaths according to World Cancer Research Fund International.
"These impressive interim results demonstrate the value of ProSense for urologists and interventional radiologists as a therapeutic alternative when patients are not eligible for surgery," stated IceCure's Chief Executive Officer, Eyal Shamir. "We believe the findings will support further use of ProSense in the jurisdictions in which our cryoablation system is approved for use with benign and malignant tissues of the kidney. The growing body of data on ProSense's efficacy and safety across a broad range of indications supports commercialization momentum, particularly in facilities that benefit from one device that can be used across multiple specialties."
ICESECRET, a prospective, multicenter, single-arm clinical trial is being performed at Bnai-Zion Medical Center, Haifa, Israel, and Shamir Medical Center, Zerifin, Israel, and led by Principal Investigator Prof. Halahmi Sarel. The trial included 115 patients (138 lesions) with localized SRM of ≤5 cm who were treated with ProSense cryoablation under CT guidance. Full engulfment of the renal lesion, including a safety margin of 0.5 cm was achieved in approximately 96% of the procedures where there was no anatomical limitation. Follow-up visits are performed 6 weeks, 6 months, 1 year, and then annually up to 5 years after the procedure. During the follow-up visits, data related to local recurrence, based on CT imaging, is collected. Safety was determined by monitoring procedure-related adverse events throughout the study.
About IceCure Medical Ltd.
IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the interim study results for ICESECRET; the value of ProSense for urologists and interventional radiologists as a therapeutic alternative when patients are not eligible for surgery; the Company's belief that the interim results from ICESECRET will support further use of ProSense in the jurisdictions in which the Company's cryoablation system is approved for use with benign and malignant tissues of the kidney; and the commercialization momentum from a growing body of data on ProSense's efficacy and safety. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities Exchange Commission (the "SEC") on April 1, 2022, as amended, which is available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
IR Contact:
Ronen Tsimerman
email: ronent@icecure-medical.com
Logo - https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
Cision
Cision
View original content:https://www.prnewswire.com/news-releases/icecures-prosense-safe-and-effective-in-treating-kidney-tumors-with-89-5-recurrence-free-rate-based-on-interim-study-results-301706491.html
SOURCE IceCure Medical Ltd
No, I got it back in early November when the insiders bought it. Just a waiting game but they bought a ton of stock so they knew this PR was gonna happen.
ICCM: Pretty impressive After Hours NEWS (LINKS below). Their COMPACT tumor-kill gadget --- which employs CRYOABLATION --- could be used to address Breast, Kidney, Bone, inter alia, cancerous tumors at EARLY stages of development. (I agree with a poster here, that said news SHOULD have been launched TOMORROW; i.e., TUESDAY morning). In any event, the proverbial SHIT will hit-the-fan at the Open behind THIS PUPPY!!!)
https://www.prnewswire.com/news-releases/icecures-prosense-safe-and-effective-in-treating-kidney-tumors-with-89-5-recurrence-free-rate-based-on-interim-study-results-301706491.html
https://www.benzinga.com/general/biotech/22/12/30136732/icecure-medical-stock-is-on-fire-after-hours-whats-going-on
https://news.yahoo.com/1-000-move-day-medical-234511255.html
what schmuck thought it was smart to release this news at 4 pm instead of tomorrow morning when more eyes would be on it
ICCM: LOVE-it, Homeboy!!! (You two Guys have SHOCKED-THE-FLICK out of me, with this After Hours stuff!!! BONKERS!!!)
ceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results
December 19 2022 - 04:05PM
PR Newswire (US)
Alert
Print
Share On Facebook
ICESECRET study interim findings presented at the Urological Association Conference in Eilat, Israel
ProSense was found to be a safe and effective treatment method for renal lesions smaller than 5 cm in patients not suitable for kidney-preserving surgery
ProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries
CAESAREA, Israel, Dec. 19, 2022 /PRNewswire/ --- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced interim results from the ICESECRET study for the treatment of patients with small renal masses ("SRM") who cannot be offered kidney-preserving surgery. Data were presented on December 14, 2022 at the Urological Association Conference in Eilat, Israel. The presentation titled "Renal Mass Cryoablation - Interim Analysis ICESECRET Study" was delivered by Dr. Nasir Said of Bnai Zion Medical Center.
IceCure Medical logo
According to the presentation, out of the 115 patients enrolled, 107 patients (112 lesions) returned for follow-up with a mean duration of 22.8 months and a range 12-60 months.
In a subgroup of patients with no previous history of kidney cancer on the same kidney and a lesion ≤3 cm, an 89.5% recurrence-free rate was observed at a mean follow-up time of 22.2 months when the procedure protocol was followed.
The recurrence-free rate was 85.1% for the 107 patients (91 patients, including 13 patients who underwent a second cryoablation), at a mean follow-up period of 16.5 months.
5 serious adverse events were reported, 4 of which were of mild severity and were treated conservatively and resolved within 1-5 days, with one severe complication of a new onset of ipsilateral hydronephrosis 7 months after the cryoablation procedure that led to nephrectomy.
Cryoablation time and hospitalization time were relatively short, up to approximately 25 minutes and 2 days, respectively.
The presentation concluded that, based on these interim results, cryoablation is safe and effective for treating renal masses under 5 cm.
According to the American Journal of Roentgenology, small renal masses, which may be malignant or benign tumors in the kidney, have been rising in incidence over the past two decades. According to the American Cancer Society, in 2022, in the U.S., an estimated 79,000 new cases of kidney cancer will be diagnosed, with about 14,000 dying from the disease. Globally, there were more than 430,000 new cases of kidney cancer in 2020 and about 180,000 deaths according to World Cancer Research Fund International.
"These impressive interim results demonstrate the value of ProSense for urologists and interventional radiologists as a therapeutic alternative when patients are not eligible for surgery," stated IceCure's Chief Executive Officer, Eyal Shamir. "We believe the findings will support further use of ProSense in the jurisdictions in which our cryoablation system is approved for use with benign and malignant tissues of the kidney. The growing body of data on ProSense's efficacy and safety across a broad range of indications supports commercialization momentum, particularly in facilities that benefit from one device that can be used across multiple specialties."
ICESECRET, a prospective, multicenter, single-arm clinical trial is being performed at Bnai-Zion Medical Center, Haifa, Israel, and Shamir Medical Center, Zerifin, Israel, and led by Principal Investigator Prof. Halahmi Sarel. The trial included 115 patients (138 lesions) with localized SRM of ≤5 cm who were treated with ProSense cryoablation under CT guidance. Full engulfment of the renal lesion, including a safety margin of 0.5 cm was achieved in approximately 96% of the procedures where there was no anatomical limitation. Follow-up visits are performed 6 weeks, 6 months, 1 year, and then annually up to 5 years after the procedure. During the follow-up visits, data related to local recurrence, based on CT imaging, is collected. Safety was determined by monitoring procedure-related adverse events throughout the study.
About IceCure Medical Ltd.
IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the
More!!!!! How do you like it, bro?
Hey bro, yeah I like that that insiders own huge. I'm new here. Hope for the best!
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
206
|
Created
|
01/20/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |